Telehealth companies including Hims & Hers Health Inc. and Noom Inc. urged an expert panel to recommend legalizing a handful of popular peptides while adding stricter oversight and a system to report side effects, according to Bloomberg.
The companies want the U.S. Food and Drug Administration to allow the peptides under a regulated framework.
Telehealth Firms Urge FDA to Legalize Peptides With Guardrails
2026-07-23 14:13:12
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
